{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:06:03Z","timestamp":1792757163394,"version":"4.5.0"},"reference-count":117,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T00:00:00Z","timestamp":1607558400000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Antimicrob Resist Infect Control"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Assessment of the burden of disease due to antimicrobial-resistant <jats:italic>Escherichia coli<\/jats:italic> infections facilitates understanding the scale of the problem and potential impacts, and comparison to other diseases, which allows prioritization of research, surveillance, and funding. Using systematic review and meta-analysis methodology, the objectives were to evaluate\u00a0whether humans\u00a0with\u00a0antimicrobial-resistant <jats:italic>E. coli<\/jats:italic>\u00a0infections experience increases in measures of\u00a0health\u00a0or\u00a0healthcare system\u00a0burden when compared to susceptible <jats:italic>E. coli<\/jats:italic> infections.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Comprehensive literature searches were performed in four primary and seven grey literature databases. Analytic observational studies of human <jats:italic>E. coli<\/jats:italic> infections that assessed the impact of resistance to third\/fourth\/fifth-generation cephalosporins, resistance to quinolones, and\/or multidrug resistance on mortality, treatment failure, length of hospital stay and\/or healthcare costs were included. Two researchers independently performed screening, data extraction, and risk of bias assessment. When possible, random effect meta-analyses followed by assessment of the confidence in the cumulative evidence were performed for mortality and length of hospital stay outcomes, and narrative syntheses were performed for treatment failure and healthcare costs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Literature searches identified 14,759 de-duplicated records and 76 articles were included. Based on 30-day and all-cause mortality meta-analyses, regardless of the type of resistance, there was a significant increase in the odds of dying with resistant <jats:italic>E. coli<\/jats:italic> infections compared to susceptible infections. A summary mean difference was not presented for total length of hospital stay meta-analyses due to substantial to considerable heterogeneity. Since small numbers of studies contributed to meta-analyses for bacterium-attributable mortality and post-infection length of hospital stay, the summary results should be considered with caution. Studies contributing results for treatment failure and healthcare costs had considerable variability in definitions and reporting.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Overall, resistant <jats:italic>E. coli<\/jats:italic> infections were associated with significant 30-day and all-cause mortality burden. More research and\/or improved reporting are necessary to facilitate quantitative syntheses of bacterium-attributable mortality, length of hospital stay, and hospital costs.<\/jats:p>\n                <jats:p><jats:italic>Protocol Registration<\/jats:italic> PROSPERO CRD42018111197.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13756-020-00863-x","type":"journal-article","created":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T11:03:40Z","timestamp":1607598220000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Evaluation of the health and healthcare system burden due to antimicrobial-resistant Escherichia coli infections in humans: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8966-2980","authenticated-orcid":false,"given":"M. C.","family":"MacKinnon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"Sargeant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. L.","family":"Pearl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. J.","family":"Reid-Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. A.","family":"Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. J.","family":"Parmley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. A.","family":"McEwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,10]]},"reference":[{"key":"863_CR1","unstructured":"World Health Organization. Antimicrobial Resistance: Global Report on Surveillance. France 2014. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/112642\/9789241564748_eng.pdf;jsessionid=5F0C8940E15B88912F38DB2241A97A94?sequence=1. Accessed 21 Jan 2018."},{"issue":"10","key":"863_CR2","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1111\/1469-0691.12798","volume":"20","author":"S Gandra","year":"2014","unstructured":"Gandra S, Barter DM, Laxminarayan R. Economic burden of antibiotic resistance: how much do we really know? Clin Microbiol Infect. 2014;20(10):973\u201380.","journal-title":"Clin Microbiol Infect"},{"key":"863_CR3","unstructured":"O\u2019Neill J. Review on Antimicrobial Resistance. Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations. 2014. https:\/\/amr-review.org\/sites\/default\/files\/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf. Accessed 29 Jun 2018."},{"issue":"6","key":"863_CR4","doi-asserted-by":"publisher","first-page":"E170","DOI":"10.1111\/j.1469-0691.2012.03845.x","volume":"18","author":"K Skogberg","year":"2012","unstructured":"Skogberg K, Lyytikainen O, Ollgren J, Nuorti JP, Ruutu P. Population-based burden of bloodstream infections in Finland. Clin Microbiol Infect. 2012;18(6):E170\u20136.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"863_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jinf.2014.01.014","volume":"69","author":"SL Nielsen","year":"2014","unstructured":"Nielsen SL, Pedersen C, Jensen TG, Gradel KO, Kolmos HJ, Lassen AT. Decreasing incidence rates of bacteremia: a 9-year population-based study. J Infect. 2014;69(1):51\u20139.","journal-title":"J Infect"},{"key":"863_CR6","unstructured":"World Health Organization. Critically important antimicrobials for human medicine, 6th revision. Switzerland 2019. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/312266\/9789241515528-eng.pdf. Accessed 13 Sep 2019."},{"issue":"1","key":"863_CR7","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12941-018-0286-5","volume":"17","author":"FY Ramirez-Castillo","year":"2018","unstructured":"Ramirez-Castillo FY, Moreno-Flores AC, Avelar-Gonzalez FJ, Marquez-Diaz F, Harel J, Guerrero-Barrera AL. An evaluation of multidrug-resistant Escherichia coli isolates in urinary tract infections from Aguascalientes, Mexico: cross-sectional study. Ann Clin Microbiol Antimicrob. 2018;17(1):34.","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"863_CR8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13756-018-0336-y","volume":"7","author":"NR Naylor","year":"2018","unstructured":"Naylor NR, Atun R, Zhu N, Kulasabanathan K, Silva S, Chatterjee A, et al. Estimating the burden of antimicrobial resistance: a systematic literature review. Antimicrob Resist Infect Control. 2018;7:58.","journal-title":"Antimicrob Resist Infect Control"},{"key":"863_CR9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1146\/annurev.publhealth.23.100901.140513","volume":"23","author":"MR Gold","year":"2002","unstructured":"Gold MR, Stevenson D, Fryback DG. HALYS and QALYS and DALYS, Oh My: similarities and differences in summary measures of population Health. Annu Rev Public Health. 2002;23:115\u201334.","journal-title":"Annu Rev Public Health"},{"issue":"1","key":"863_CR10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S1473-3099(18)30605-4","volume":"19","author":"A Cassini","year":"2019","unstructured":"Cassini A, Hogberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019;19(1):56\u201366.","journal-title":"Lancet Infect Dis"},{"key":"863_CR11","unstructured":"MacKinnon MC, Sargeant JM, Pearl DL, Reid-Smith RJ, Carson CA, Parmley EJ, et al. A protocol for a systematic review and meta-analysis of the health and healthcare system burden due to human Escherichia coli infections resistant to third\/fourth\/fifth generation cephalosporins or quinolones, or with multidrug resistance. CRD42018111197 PROSPERO. 2018. https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?RecordID=111197."},{"issue":"7","key":"863_CR12","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.","journal-title":"PLoS Med"},{"key":"863_CR13","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.","journal-title":"BMJ"},{"key":"863_CR14","unstructured":"Dohoo IR, Stryhn H, Martin SW. Veterinary Epidemiologic Research, 2nd ed.: VER Inc.; 2012."},{"key":"863_CR15","unstructured":"World Health Organization. Critically important antimicrobials for human medicine, 5th revision. Switzerland 2017. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/255027\/9789241512220-eng.pdf?sequence=1. Accessed 20 Jun 2018."},{"issue":"3","key":"863_CR16","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"AP Magiorakos","year":"2012","unstructured":"Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268\u201381.","journal-title":"Clin Microbiol Infect"},{"key":"863_CR17","unstructured":"Clarivate Anaytics. EndNote X7. 2016."},{"key":"863_CR18","unstructured":"Clarivate Analytics. EndNote X9. 2018."},{"key":"863_CR19","unstructured":"Evidence Partners. DistillerSR. Ottawa, Canada."},{"key":"863_CR20","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.","journal-title":"BMJ"},{"key":"863_CR21","unstructured":"The World Bank. World Bank Country and Lending Groups: Classification 2018 https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/255027\/9789241512220-eng.pdf?sequence=1. Accessed 20 Jun 2018."},{"key":"863_CR22","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2019."},{"key":"863_CR23","unstructured":"RStudio Team. RStudio: Integrated Development for R. RStudio, Inc. Boston, MA2018."},{"issue":"4","key":"863_CR24","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22(4):153\u201360.","journal-title":"Evid Based Ment Health"},{"key":"863_CR25","doi-asserted-by":"crossref","unstructured":"Deeks JJ, Higgins JPT, Altman DG, (editors). Analysing data and undertaking meta-analyses. 2019. In: Cochrane handbook for systematic reviews of interventions version 60 (updated July 2019) Cochrane. www.training.cochrane.org\/handbook.","DOI":"10.1002\/9781119536604.ch10"},{"key":"863_CR26","unstructured":"Kossmeier M, Tran US, Voracek M. metaviz: Forest Plots, Funnel Plots, and Visual Funnel Plot Inference for Meta-Analysis. R package version 0.3.0. 2019."},{"issue":"4","key":"863_CR27","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383\u201394.","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"863_CR28","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","volume":"64","author":"H Balshem","year":"2011","unstructured":"Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401\u20136.","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"863_CR29","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.jclinepi.2010.07.017","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence\u2013study limitations (risk of bias). J Clin Epidemiol. 2011;64(4):407\u201315.","journal-title":"J Clin Epidemiol."},{"issue":"12","key":"863_CR30","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/j.jclinepi.2011.04.014","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 8. Rating the quality of evidence\u2013indirectness. J Clin Epidemiol. 2011;64(12):1303\u201310.","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"863_CR31","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.jclinepi.2011.03.017","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al. GRADE guidelines: 7. Rating the quality of evidence\u2013inconsistency. J Clin Epidemiol. 2011;64(12):1294\u2013302.","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"863_CR32","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.jclinepi.2011.01.011","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Montori V, Vist G, Kunz R, Brozek J, et al. GRADE guidelines: 5. Rating the quality of evidence\u2013publication bias. J Clin Epidemiol. 2011;64(12):1277\u201382.","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"863_CR33","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence\u2013imprecision. J Clin Epidemiol. 2011;64(12):1283\u201393.","journal-title":"J Clin Epidemiol."},{"issue":"12","key":"863_CR34","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/j.jclinepi.2011.06.004","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, et al. GRADE guidelines: 9. Rating up the quality of evidence. J Clin Epidemiol. 2011;64(12):1311\u20136.","journal-title":"J Clin Epidemiol"},{"key":"863_CR35","unstructured":"Evidence Prime Inc. GRADEpro GDT: GRADEpro Guideline Development Tool. McMaster University; 2015. https:\/\/gradepro.org\/. Accessed 20 Oct 2019."},{"key":"863_CR36","doi-asserted-by":"crossref","unstructured":"Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, et al. GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes. J Clin Epidemiol. 2013;66(2):158-72.","DOI":"10.1016\/j.jclinepi.2012.01.012"},{"issue":"3","key":"863_CR37","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.4081\/cp.2012.e76","volume":"2","author":"G Alvarez-Uria","year":"2012","unstructured":"Alvarez-Uria G, Priyadarshini U, Naik PK, Midde M, Reddy R. Mortality associated with community-acquired cephalosporin-resistant Escherichia coli in patients admitted to a district hospital in a resource-limited setting. Clin Pract. 2012;2(3):e76.","journal-title":"Clin Pract"},{"issue":"7 SUPPL.","key":"863_CR38","first-page":"1210","volume":"6","author":"A Chakraborty","year":"2012","unstructured":"Chakraborty A, Adhikari P, Shenoy S, Baliga S, Rao S, Dhanashree B. Extra-intestinal beta-lactamase producing Escherichia coli infection-an emerging infection in a South Indian tertiary care hospital. J Clin Diagn Res. 2012;6(7 SUPPL.):1210\u20134.","journal-title":"J Clin Diagn Res"},{"issue":"12","key":"863_CR39","first-page":"1271","volume":"65","author":"A Parveen","year":"2015","unstructured":"Parveen A, Sultan F, Raza A, Zafar W, Nizamuddin S, Mahboob A, et al. Bacteraemia caused by Escherichia coli in cancer patients at a specialist center in Pakistan. J Pak Med Assoc. 2015;65(12):1271\u20136.","journal-title":"J Pak Med Assoc"},{"issue":"6","key":"863_CR40","first-page":"100","volume":"14","author":"S Chauhan","year":"2015","unstructured":"Chauhan S. Evaluation of risk factors and clinical outcome related to ESBL-producing E. coli infection among hospitalized patients. IOSR-JDMS. 2015;14(6):100\u20134.","journal-title":"IOSR-JDMS"},{"issue":"4","key":"863_CR41","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/cid\/ciu864","volume":"60","author":"F Can","year":"2015","unstructured":"Can F, Azap OK, Seref C, Ispir P, Arslan H, Ergonul O. Emerging Escherichia coli O25b\/ST131 clone predicts treatment failure in urinary tract infections. Clin Infect Dis. 2015;60(4):523\u20137.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"863_CR42","first-page":"1169","volume":"43","author":"S Anunnatsiri","year":"2012","unstructured":"Anunnatsiri S, Towiwat P, Chaimanee P. Risk factors and clinical outcomes of extended spectrum beta-lactamase (ESBL)-producing Escherichia coli septicemia at Srinagarind University Hospital, Thailand. Southeast Asian J Trop Med Public Health. 2012;43(5):1169\u201377.","journal-title":"Southeast Asian J Trop Med Public Health"},{"issue":"1","key":"863_CR43","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1086\/524321","volume":"29","author":"A Apisarnthanarak","year":"2008","unstructured":"Apisarnthanarak A, Kiratisin P, Saifon P, Kitphati R, Dejsirilert S, Mundy LM. Predictors of mortality among patients with community-onset infection due to extended-spectrum beta-lactamase-producing Escherichia coli in Thailand. Infect Control Hosp Epidemiol. 2008;29(1):80\u20132.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"4","key":"863_CR44","doi-asserted-by":"publisher","first-page":"e35780","DOI":"10.1371\/journal.pone.0035780","volume":"7","author":"P Cornejo-Juarez","year":"2012","unstructured":"Cornejo-Juarez P, Perez-Jimenez C, Silva-Sanchez J, Velazquez-Acosta C, Gonzalez-Lara F, Reyna-Flores F, et al. Molecular analysis and risk factors for Escherichia coli producing extended-spectrum beta-lactamase bloodstream infection in hematological malignancies. PLoS ONE. 2012;7(4):e35780.","journal-title":"PLoS ONE"},{"issue":"09","key":"863_CR45","doi-asserted-by":"publisher","first-page":"e18082","DOI":"10.7554\/eLife.18082","volume":"5","author":"C Lim","year":"2016","unstructured":"Lim C, Takahashi E, Hongsuwan M, Wuthiekanun V, Thamlikitkul V, Hinjoy S, et al. Epidemiology and burden of multidrug-resistant bacterial infection in a developing country. elife. 2016;5(09):e18082.","journal-title":"elife"},{"issue":"7","key":"863_CR46","doi-asserted-by":"publisher","first-page":"507","DOI":"10.3855\/jidc.2788","volume":"7","author":"O Kaya","year":"2013","unstructured":"Kaya O, Akcam FZ, Gonen I, Unal O, Ceylan T. Risk factors for bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli in a Turkish hospital. J Infect Dev Ctries. 2013;7(7):507\u201312.","journal-title":"J Infect Dev Ctries"},{"issue":"3","key":"863_CR47","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3747\/pdi.2013.00012","volume":"34","author":"XR Feng","year":"2014","unstructured":"Feng XR, Yang X, Yi CY, Guo QY, Mao HP, Jiang ZP, et al. Escherichia coli peritonitis in peritoneal dialysis: the prevalence, antibiotic resistance and clinical outcomes in a south China dialysis center. Perit Dial Int. 2014;34(3):308\u201316.","journal-title":"Perit Dial Int"},{"issue":"21","key":"863_CR48","doi-asserted-by":"publisher","first-page":"E6959","DOI":"10.1097\/MD.0000000000006959","volume":"96","author":"J Ma","year":"2017","unstructured":"Ma J, Li N, Liu YJ, Wang C, Liu XY, Chen SM, et al. Antimicrobial resistance patterns, clinical features, and risk factors for septic shock and death of nosocomial E. coli bacteremia in adult patients with hematological disease: a monocenter retrospective study in China. Medicine (Baltimore). 2017;96(21):E6959.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"863_CR49","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1093\/jac\/dkq412","volume":"66","author":"ME de Kraker","year":"2011","unstructured":"de Kraker ME, Wolkewitz M, Davey PG, Koller W, Berger J, Nagler J, et al. Burden of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay associated with bloodstream infections due to Escherichia coli resistant to third-generation cephalosporins. J Antimicrob Chemother. 2011;66(2):398\u2013407.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"863_CR50","doi-asserted-by":"publisher","first-page":"251.e1","DOI":"10.1016\/j.cmi.2015.01.001","volume":"21","author":"JK Abernethy","year":"2015","unstructured":"Abernethy JK, Johnson AP, Guy R, Hinton N, Sheridan EA, Hope RJ. Thirty day all-cause mortality in patients with Escherichia coli bacteraemia in England. Clin Microbiol Infect. 2015;21(3):251.e1\u20138.","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"863_CR51","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.ijantimicag.2010.05.009","volume":"36","author":"CI Kang","year":"2010","unstructured":"Kang CI, Song JH, Chung DR, Peck KR, Ko KS, Yeom JS, et al. Risk factors and treatment outcomes of community-onset bacteraemia caused by extended-spectrum beta-lactamase-producing Escherichia coli. Int J Antimicrob Agents. 2010;36(3):284\u20137.","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"863_CR52","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3109\/00365548.2010.539257","volume":"43","author":"CI Kang","year":"2011","unstructured":"Kang CI, Chung DR, Ko KS, Peck KR, Song JH, Korean Network for the Study of Infectious Diseases. Risk factors for mortality and impact of broad-spectrum cephalosporin resistance on outcome in bacteraemic intra-abdominal infections caused by Gram-negative bacilli. Scand J Infect Dis. 2011;43(3):202\u20138.","journal-title":"Scand J Infect Dis"},{"issue":"1","key":"863_CR53","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/S1473-3099(10)70258-9","volume":"11","author":"ML Lambert","year":"2011","unstructured":"Lambert ML, Suetens C, Savey A, Palomar M, Hiesmayr M, Morales I, et al. Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: a cohort study. Lancet Infect Dis. 2011;11(1):30\u20138.","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"863_CR54","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s10096-003-0975-6","volume":"22","author":"K Huotari","year":"2003","unstructured":"Huotari K, Tarkka E, Valtonen V, Kolho E. Incidence and risk factors for nosocomial infections caused by fluoroquinolone-resistant Escherichia coli. Eur J Clin Microbiol Infect Dis. 2003;22(8):492\u20135.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"4","key":"863_CR55","doi-asserted-by":"publisher","first-page":"e0153076","DOI":"10.1371\/journal.pone.0153076","volume":"11","author":"M Riu","year":"2016","unstructured":"Riu M, Chiarello P, Terradas R, Sala M, Garcia-Alzorriz E, Castells X, et al. Cost attributable to nosocomial bacteremia. Analysis according to microorganism and antimicrobial sensitivity in a university hospital in Barcelona. PLoS ONE. 2016;11(4):e0153076.","journal-title":"PLoS ONE"},{"issue":"3","key":"863_CR56","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3109\/23744235.2015.1109135","volume":"48","author":"T Martelius","year":"2016","unstructured":"Martelius T, Jalava J, Karki T, Mottonen T, Ollgren J, Lyytikainen O, et al. Nosocomial bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae resistant to third-generation cephalosporins, Finland, 1999\u20132013: trends, patient characteristics and mortality. Infect Dis (Lond). 2016;48(3):229\u201334.","journal-title":"Infect Dis (Lond)."},{"issue":"4","key":"863_CR57","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1093\/jac\/dkm279","volume":"60","author":"G Peralta","year":"2007","unstructured":"Peralta G, Sanchez MB, Garrido JC, De Benito I, Cano ME, Martinez-Martinez L, et al. Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia. J Antimicrob Chemother. 2007;60(4):855\u201363.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"863_CR58","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1093\/jac\/dkn514","volume":"63","author":"M Ortega","year":"2009","unstructured":"Ortega M, Marco F, Soriano A, Almela M, Martinez JA, Munoz A, et al. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome. J Antimicrob Chemother. 2009;63(3):568\u201374.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"863_CR59","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jinf.2009.02.002","volume":"58","author":"EM Trecarichi","year":"2009","unstructured":"Trecarichi EM, Tumbarello M, Spanu T, Caira M, Fianchi L, Chiusolo P, et al. Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. J Infect. 2009;58(4):299\u2013307.","journal-title":"J Infect"},{"issue":"6","key":"863_CR60","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1093\/jac\/dkm378","volume":"60","author":"HS Cheong","year":"2007","unstructured":"Cheong HS, Kang CI, Kwon KT, Heo ST, Wi YM, Kim ES, et al. Clinical significance of healthcare-associated infections in community-onset Escherichia coli bacteraemia. J Antimicrob Chemother. 2007;60(6):1355\u201360.","journal-title":"J Antimicrob Chemother"},{"key":"863_CR61","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ebiom.2018.08.029","volume":"35","author":"EJ Yoon","year":"2018","unstructured":"Yoon EJ, Choi MH, Park YS, Lee HS, Kim D, Lee H, et al. Impact of host-pathogen-treatment tripartite components on early mortality of patients with Escherichia coli bloodstream infection: prospective observational study. EBioMedicine. 2018;35:76\u201386.","journal-title":"EBioMedicine"},{"issue":"2","key":"863_CR62","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s40121-017-0152-3","volume":"6","author":"AS Uzodi","year":"2017","unstructured":"Uzodi AS, Lohse CM, Banerjee R. Risk factors for and outcomes of multidrug-resistant Escherichia coli infections in children. Infect Dis Ther. 2017;6(2):245\u201357.","journal-title":"Infect Dis Ther"},{"issue":"3","key":"863_CR63","doi-asserted-by":"publisher","first-page":"e01709","DOI":"10.1128\/AAC.01709-16","volume":"61","author":"JT Thaden","year":"2017","unstructured":"Thaden JT, Li YH, Ruffin F, Maskarinec SA, Hill-Rorie JM, Wanda LC, et al. Increased costs associated with bloodstream infections caused by multidrug-resistant gram-negative bacteria are due primarily to patients with hospital-acquired infections. Antimicrob Agents Chemother. 2017;61(3):e01709\u201316.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"863_CR64","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1080\/00365540210147516","volume":"34","author":"PL Ho","year":"2002","unstructured":"Ho PL, Chan WM, Tsang KWT, Wong SSY, Young K. Bacteremia caused by Escherichia coli producing extended-spectrum beta-lactamase: a case-control study of risk factors and outcomes. Scand J Infect Dis. 2002;34(8):567\u201373.","journal-title":"Scand J Infect Dis"},{"issue":"3","key":"863_CR65","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jinf.2007.04.007","volume":"55","author":"M Melzer","year":"2007","unstructured":"Melzer M, Petersen I. Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli. J Infect. 2007;55(3):254\u20139.","journal-title":"J Infect"},{"issue":"2","key":"863_CR66","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jhin.2007.11.012","volume":"68","author":"C Pena","year":"2008","unstructured":"Pena C, Gudiol C, Calatayud L, Tubau F, Dominguez MA, Pujol M, et al. Infections due to Escherichia coli producing extended-spectrum beta-lactamase among hospitalised patients: factors influencing mortality. J Hosp Infect. 2008;68(2):116\u201322.","journal-title":"J Hosp Infect"},{"issue":"2","key":"863_CR67","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1093\/jac\/dkp411","volume":"65","author":"C Gudiol","year":"2010","unstructured":"Gudiol C, Calatayud L, Garcia-Vidal C, Lora-Tamayo J, Cisnal M, Duarte R, et al. Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. J Antimicrob Chemother. 2010;65(2):333\u201341.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"863_CR68","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/S1684-1182(10)60038-2","volume":"43","author":"CJ Hsieh","year":"2010","unstructured":"Hsieh CJ, Shen YH, Hwang KP. Clinical implications, risk factors and mortality following community-onset bacteremia caused by extended-spectrum beta-lactamase (ESBL) and non-ESBL producing Escherichia coli. J Microbiol Immunol Infect. 2010;43(3):240\u20138.","journal-title":"J Microbiol Immunol Infect"},{"issue":"4","key":"863_CR69","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1089\/mdr.2011.0072","volume":"17","author":"SH Park","year":"2011","unstructured":"Park SH, Choi SM, Lee DG, Kim J, Choi JH, Kim SH, et al. Emergence of extended-spectrum beta-lactamase-producing Escherichia coli as a cause of community-onset bacteremia in South Korea: Risk factors and clinical outcomes. Microb Drug Resist. 2011;17(4):537\u201344.","journal-title":"Microb Drug Resist"},{"issue":"5","key":"863_CR70","doi-asserted-by":"publisher","first-page":"e371","DOI":"10.1016\/j.ijid.2012.01.008","volume":"16","author":"JT Freeman","year":"2012","unstructured":"Freeman JT, McBride SJ, Nisbet MS, Gamble GD, Williamson DA, Taylor SL, et al. Bloodstream infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care hospital in New Zealand: risk factors and outcomes. Int J Infect Dis. 2012;16(5):e371\u20134.","journal-title":"Int J Infect Dis"},{"issue":"2","key":"863_CR71","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1128\/JCM.06002-11","volume":"50","author":"CI Kang","year":"2012","unstructured":"Kang CI, Wi YM, Lee MY, Ko KS, Chung DR, Peck KR, et al. Epidemiology and risk factors of community onset infections caused by extended-spectrum beta-lactamase-producing Escherichia coli strains. J Clin Microbiol. 2012;50(2):312\u20137.","journal-title":"J Clin Microbiol"},{"issue":"5","key":"863_CR72","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.ijantimicag.2013.07.018","volume":"42","author":"YE Ha","year":"2013","unstructured":"Ha YE, Kang CI, Cha MK, Park SY, Wi YM, Chung DR, et al. Epidemiology and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in patients with cancer. Int J Antimicrob Agents. 2013;42(5):403\u20139.","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"863_CR73","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00277-012-1631-y","volume":"92","author":"SH Kim","year":"2013","unstructured":"Kim SH, Kwon JC, Choi SM, Lee DG, Park SH, Choi JH, et al. Escherichia coli and Klebsiella pneumoniae bacteremia in patients with neutropenic fever: factors associated with extended-spectrum beta-lactamase production and its impact on outcome. Ann Hematol. 2013;92(4):533\u201341.","journal-title":"Ann Hematol"},{"key":"863_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijid.2015.07.010","volume":"39","author":"B Denis","year":"2015","unstructured":"Denis B, Lafaurie M, Donay JL, Fontaine JP, Oksenhendler E, Raffoux E, et al. Prevalence, risk factors, and impact on clinical outcome of extended-spectrum beta-lactamase-producing Escherichia coli bacteraemia: a five-year study. Int J Infect Dis. 2015;39:1\u20136.","journal-title":"Int J Infect Dis"},{"issue":"6","key":"863_CR75","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.jinf.2015.08.012","volume":"71","author":"E Esteve-Palau","year":"2015","unstructured":"Esteve-Palau E, Solande G, Sanchez F, Sorli L, Montero M, Guerri R, et al. Clinical and economic impact of urinary tract infections caused by ESBL-producing Escherichia coli requiring hospitalization: a matched cohort study. J Infect. 2015;71(6):667\u201374.","journal-title":"J Infect"},{"key":"863_CR76","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.jiac.2018.04.016","volume":"24","author":"Y Haruki","year":"2018","unstructured":"Haruki Y, Hagiya H, Haruki M, Sugiyama T. Clinical characteristics and outcome of critically ill patients with bacteremia caused by extended-spectrum beta-lactamase-producing and non-producing Escherichia coli. J Infect Chemother. 2018;24:944\u20137.","journal-title":"J Infect Chemother"},{"issue":"3","key":"863_CR77","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1089\/107662902760326959","volume":"8","author":"JS Eom","year":"2002","unstructured":"Eom JS, Hwang BY, Sohn JW, Kim WJ, Kim MJ, Park SC, et al. Clinical and molecular epidemiology of quinolone-resistant Escherichia coli isolated from urinary tract infection. Microb Drug Resist. 2002;8(3):227\u201334.","journal-title":"Microb Drug Resist"},{"issue":"6","key":"863_CR78","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/jhm.877","volume":"6","author":"BC Camins","year":"2011","unstructured":"Camins BC, Marschall J, DeVader SR, Maker DE, Hoffman MW, Fraser VJ. The clinical impact of fluoroquinolone resistance in patients with E. coli bacteremia. J Hosp Med. 2011;6(6):344\u20139.","journal-title":"J Hosp Med"},{"issue":"5","key":"863_CR79","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/liv.12374","volume":"34","author":"J Kim","year":"2014","unstructured":"Kim J, Kang CI, Joo EJ, Ha YE, Cho SY, Gwak GY, et al. Risk factor of community-onset spontaneous bacterial peritonitis caused by fluoroquinolone-resistant Escherichia coli in patients with cirrhosis. Liver Int. 2014;34(5):695\u20139.","journal-title":"Liver Int"},{"issue":"2","key":"863_CR80","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s15010-006-4114-z","volume":"34","author":"R Henshke-Bar-Meir","year":"2006","unstructured":"Henshke-Bar-Meir R, Yinnon AM, Rudensky B, Attias D, Schlesinger Y, Raveh D. Assessment of the clinical significance of production of extended-spectrum beta-lactamases (ESBL) by Enterobacteriaceae. Infection. 2006;34(2):66\u201374.","journal-title":"Infection"},{"issue":"2","key":"863_CR81","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1177\/089686080602600213","volume":"26","author":"T Yip","year":"2006","unstructured":"Yip T, Tse KC, Lam MF, Tang S, Li FK, Choy BY, et al. Risk factors and outcomes of extended-spectrum beta-lactamase-producing E-coli peritonitis in CAPD patients. Perit Dial Int. 2006;26(2):191\u20137.","journal-title":"Perit Dial Int"},{"issue":"6","key":"863_CR82","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.tmaid.2010.10.004","volume":"8","author":"FY Khan","year":"2010","unstructured":"Khan FY, Elshafie SS, Almaslamani M, Abu-Khattab M, El Hiday AH, Errayes M, et al. Epidemiology of bacteraemia in Hamad general hospital, Qatar: a one year hospital-based study. Travel Med Infect Dis. 2010;8(6):377\u201387.","journal-title":"Travel Med Infect Dis"},{"issue":"1","key":"863_CR83","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1086\/649537","volume":"50","author":"J Rodriguez-Bano","year":"2010","unstructured":"Rodriguez-Bano J, Picon E, Gijon P, Hernandez JR, Ruiz M, Pena C, et al. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis. 2010;50(1):40\u20138.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"863_CR84","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.1128\/AAC.00143-10","volume":"54","author":"M Tumbarello","year":"2010","unstructured":"Tumbarello M, Spanu T, Di Bidino R, Marchetti M, Ruggeri M, Trecarichi EM, et al. Costs of bloodstream infections caused by Escherichia coli and influence of extended-spectrum-beta-lactamase production and inadequate initial antibiotic therapy. Antimicrob Agents Chemother. 2010;54(10):4085\u201391.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"863_CR85","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/j.1469-0691.2010.03298.x","volume":"17","author":"A Courpon-Claudinon","year":"2011","unstructured":"Courpon-Claudinon A, Lefort A, Panhard X, Clermont O, Dornic Q, Fantin B, et al. Bacteraemia caused by third-generation cephalosporin-resistant Escherichia coli in France: prevalence, molecular epidemiology and clinical features. Clin Microbiol Infect. 2011;17(4):557\u201365.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"863_CR86","doi-asserted-by":"publisher","first-page":"e30498","DOI":"10.1371\/journal.pone.0030498","volume":"7","author":"MH Nicolas-Chanoine","year":"2012","unstructured":"Nicolas-Chanoine MH, Jarlier V, Robert J, Arlet G, Drieux L, Leflon-Guibout V, et al. Patient\u2019s origin and lifestyle associated with CTX-M-producing Escherichia coli: a case\u2013control\u2013control study. PLoS ONE. 2012;7(1):e30498.","journal-title":"PLoS ONE"},{"issue":"2","key":"863_CR87","first-page":"171","volume":"34","author":"FE Al-Otaibi","year":"2013","unstructured":"Al-Otaibi FE, Bukhari EE. Clinical and laboratory profiles of urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in a tertiary care center in central Saudi Arabia. Saudi Med J. 2013;34(2):171\u20136.","journal-title":"Saudi Med J"},{"key":"863_CR88","doi-asserted-by":"publisher","first-page":"50","DOI":"10.4236\/aid.2013.31006","volume":"3","author":"A Nussbaum","year":"2013","unstructured":"Nussbaum A, Mariano N, Colon-Urban R, Modeste RA, Zahid S, Wehbeh W, et al. Microbiologic and clinical comparison of patients harboring Escherichia coli blood isolates with and without extended-spectrum \u03b2-lactamases. Adv Infect Dis. 2013;3:50\u20134.","journal-title":"Adv Infect Dis"},{"issue":"1","key":"863_CR89","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1089\/mdr.2013.0075","volume":"20","author":"S Lee","year":"2014","unstructured":"Lee S, Song DY, Cho SH, Kwon KT. Impact of extended-spectrum beta-lactamase on acute pyelonephritis teated with empirical ceftriaxone. Microb Drug Resist. 2014;20(1):39\u201344.","journal-title":"Microb Drug Resist"},{"key":"863_CR90","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2147\/IDR.S56984","volume":"7","author":"R Leistner","year":"2014","unstructured":"Leistner R, Sakellariou C, Gurntke S, Kola A, Steinmetz I, Kohler C, et al. Mortality and molecular epidemiology associated with extended-spectrum beta-lactamase production in Escherichia coli from bloodstream infection. Infect Drug Resist. 2014;7:57\u201362.","journal-title":"Infect Drug Resist"},{"issue":"6","key":"863_CR91","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s15010-014-0670-9","volume":"42","author":"R Leistner","year":"2014","unstructured":"Leistner R, Gurntke S, Sakellariou C, Denkel LA, Bloch A, Gastmeier P, et al. Bloodstream infection due to extended-spectrum beta-lactamase (ESBL)-positive K. pneumoniae and E. coli: an analysis of the disease burden in a large cohort. Infection. 2014;42(6):991\u20137.","journal-title":"Infection"},{"issue":"11","key":"863_CR92","doi-asserted-by":"publisher","first-page":"753","DOI":"10.3109\/00365548.2014.937454","volume":"46","author":"S Van Aken","year":"2014","unstructured":"Van Aken S, Lund N, Ahl J, Odenholt I, Tham J. Risk factors, outcome and impact of empirical antimicrobial treatment in extended-spectrum beta-lactamase-producing Escherichia coli bacteraemia. Scand J Infect Dis. 2014;46(11):753\u201362.","journal-title":"Scand J Infect Dis"},{"issue":"1","key":"863_CR93","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jhin.2015.10.001","volume":"92","author":"JA Maslikowska","year":"2016","unstructured":"Maslikowska JA, Walker SAN, Elligsen M, Mittmann N, Palmay L, Daneman N, et al. Impact of infection with extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella species on outcome and hospitalization costs. J Hosp Infect. 2016;92(1):33\u201341.","journal-title":"J Hosp Infect"},{"issue":"4","key":"863_CR94","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1128\/AAC.04821-14","volume":"59","author":"SH Park","year":"2015","unstructured":"Park SH, Choi SM, Lee DG, Cho SY, Lee HJ, Choi JK, et al. Impact of extended-spectrum beta-lactamase production on treatment outcomes of acute pyelonephritis caused by Escherichia coli in patients without health care-associated risk factors. Antimicrob Agents Chemother. 2015;59(4):1962\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"863_CR95","doi-asserted-by":"publisher","first-page":"e13001","DOI":"10.1111\/ijcp.13001","volume":"71","author":"A Artero","year":"2017","unstructured":"Artero A, Esparcia A, Alberola J, Madrazo M, Nogueira JM, Eiros JM. Prospective cohort study of risk factors for extended-spectrum \u03b2-lactamase-producing Escherichia coli urinary tract infections in elderly patients admitted to hospital. Int J Clin Pract. 2017;71(9):e13001.","journal-title":"Int J Clin Pract"},{"issue":"14","key":"863_CR96","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.2169\/internalmedicine.56.7702","volume":"56","author":"H Namikawa","year":"2017","unstructured":"Namikawa H, Yamada K, Fujimoto H, Oinuma KI, Tochino Y, Takemoto Y, et al. Clinical characteristics of bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli at a tertiary hospital. Intern Med. 2017;56(14):1807\u201315.","journal-title":"Intern Med"},{"issue":"2","key":"863_CR97","first-page":"119","volume":"71","author":"YY Huang","year":"2018","unstructured":"Huang YY, Alleyne A, Leung V, Chapman M. Urosepsis due to extended-spectrum beta-lactamase-producing Escherichia coli: a retrospective, single-centre review of risk factors and clinical outcomes. Can J Hosp Pharm. 2018;71(2):119\u201327.","journal-title":"Can J Hosp Pharm"},{"issue":"8","key":"863_CR98","doi-asserted-by":"publisher","first-page":"e0202276","DOI":"10.1371\/journal.pone.0202276","volume":"13","author":"Y Komatsu","year":"2018","unstructured":"Komatsu Y, Kasahara K, Inoue T, Lee ST, Muratani T, Yano H, et al. Molecular epidemiology and clinical features of extended-spectrum beta-lactamase- or carbapenemase-producing Escherichia coli bacteremia in Japan. PLoS ONE. 2018;13(8):e0202276.","journal-title":"PLoS ONE"},{"issue":"9","key":"863_CR99","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/j.ajem.2018.01.046","volume":"36","author":"H Lee","year":"2018","unstructured":"Lee H, Han SB, Kim JH, Kang S, Durey A. Risk factors of urinary tract infection caused by extended spectrum beta-lactamase-producing Escherichia coli in emergency department. Am J Emerg Med. 2018;36(9):1608\u201312.","journal-title":"Am J Emerg Med"},{"issue":"11","key":"863_CR100","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1128\/AAC.43.11.2736","volume":"43","author":"J Garau","year":"1999","unstructured":"Garau J, Xercavins M, Rodriguez-Carballeira M, Gomez-Vera JR, Coll I, Vidal D, et al. Emergence and dissemination of quinolone-resistant Escherichia coli in the community. Antimicrob Agents Chemother. 1999;43(11):2736\u201341.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"863_CR101","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1086\/320873","volume":"33","author":"HJ Cheong","year":"2001","unstructured":"Cheong HJ, Yoo CW, Sohn JW, Kim WJ, Kim MJ, Park SC. Bacteremia due to quinolone-resistant Escherichia coli in a teaching hospital in South Korea. Clin Infect Dis. 2001;33(1):48\u201353.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"863_CR102","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1046\/j.1365-2036.2003.01491.x","volume":"17","author":"F Cereto","year":"2003","unstructured":"Cereto F, Molina I, Gonzalez A, Del Valle O, Esteban R, Guardia J, et al. Role of immunosuppression in the development of quinolone-resistant Escherichia coli spontaneous bacterial peritonitis and in the mortality of E. coli spontaneous bacterial peritonitis. Aliment Pharmacol Ther. 2003;17(5):695\u2013701.","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"863_CR103","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1111\/j.1469-0691.2008.02088.x","volume":"14","author":"F Bert","year":"2008","unstructured":"Bert F, Panhard X, Johnson J, Lecuyer H, Moreau R, Le Grand J, et al. Genetic background of Escherichia coli isolates from patients with spontaneous bacterial peritonitis: relationship with host factors and prognosis. Clin Microbiol Infect. 2008;14(11):1034\u201340.","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"863_CR104","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1097\/MEG.0b013e3282fc7390","volume":"20","author":"F Cereto","year":"2008","unstructured":"Cereto F, Herranz X, Moreno E, Andreu A, Vergara M, Fontanals D, et al. Role of host and bacterial virulence factors in Escherichia coli spontaneous bacterial peritonitis. Eur J Gastroenterol Hepatol. 2008;20(9):924\u20139.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"11","key":"863_CR105","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1111\/j.1469-0691.2008.02089.x","volume":"14","author":"KB Laupland","year":"2008","unstructured":"Laupland KB, Gregson DB, Church DL, Ross T, Pitout JDD. Incidence, risk factors and outcomes of Escherichia coli bloodstream infections in a large Canadian region. Clin Microbiol Infect. 2008;14(11):1041\u20137.","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"863_CR106","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1089\/mdr.2011.0139","volume":"18","author":"J Shin","year":"2012","unstructured":"Shin J, Kim J, Wie SH, Cho YK, Lim SK, Shin SY, et al. Fluoroquinolone resistance in uncomplicated acute pyelonephritis: epidemiology and clinical impact. Microb Drug Resist. 2012;18(2):169\u201375.","journal-title":"Microb Drug Resist"},{"issue":"9","key":"863_CR107","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1093\/jac\/dky230","volume":"73","author":"M Bollestad","year":"2018","unstructured":"Bollestad M, Grude N, Solhaug S, Raffelsberger N, Handal N, Nilsen HS, et al. Clinical and bacteriological efficacy of pivmecillinam treatment for uncomplicated urinary tract infections caused by ESBL-producing Escherichia coli: a prospective, multicentre, observational cohort study. J Antimicrob Chemother. 2018;73(9):2503\u20139.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"863_CR108","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jmii.2013.05.006","volume":"47","author":"NC Fan","year":"2014","unstructured":"Fan NC, Chen HH, Chen CL, Ou LS, Lin TY, Tsai MH, et al. Rise of community-onset urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli in children. J Microbiol Immunol Infect. 2014;47(5):399\u2013405.","journal-title":"J Microbiol Immunol Infect"},{"issue":"1","key":"863_CR109","doi-asserted-by":"publisher","first-page":"e85889","DOI":"10.1371\/journal.pone.0085889","volume":"9","author":"A Soraas","year":"2014","unstructured":"Soraas A, Sundsfjord A, Jorgensen SB, Liestol K, Jenum PA. High rate of per oral mecillinam treatment failure in community-acquired urinary tract infections caused by ESBL-producing Escherichia coli. PLoS ONE. 2014;9(1):e85889.","journal-title":"PLoS ONE"},{"issue":"6","key":"863_CR110","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1128\/AAC.06212-11","volume":"56","author":"JH Jeon","year":"2012","unstructured":"Jeon JH, Kim K, Han WD, Song SH, Park KU, Rhee JE, et al. Empirical use of ciprofloxacin for acute uncomplicated pyelonephritis caused by Escherichia coli in communities where the prevalence of fluoroquinolone resistance is high. Antimicrob Agents Chemother. 2012;56(6):3043\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"863_CR111","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jinf.2008.07.004","volume":"57","author":"C Gagliotti","year":"2008","unstructured":"Gagliotti C, Buttazzi R, Sforza S, Moro ML, Emilia-Romagna Antibiotic Resistance Study Group. Resistance to fluoroquinolones and treatment failure\/short-term relapse of community-acquired urinary tract infections caused by Escherichia coli. J Infect. 2008;57(3):179\u201384.","journal-title":"J Infect"},{"issue":"2","key":"863_CR112","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jgar.2014.01.005","volume":"2","author":"R Leistner","year":"2014","unstructured":"Leistner R, Bloch A, Sakellariou C, Gastmeier P, Schwab F. Costs and length of stay associated with extended-spectrum beta-lactamase production in cases of Escherichia coli bloodstream infection. J Glob Antimicrob Resist. 2014;2(2):107\u20139.","journal-title":"J Glob Antimicrob Resist"},{"issue":"5","key":"863_CR113","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1093\/jac\/dkm318","volume":"60","author":"MJ Schwaber","year":"2007","unstructured":"Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother. 2007;60(5):913\u201320.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"863_CR114","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1093\/jac\/dks065","volume":"67","author":"WC Rottier","year":"2012","unstructured":"Rottier WC, Ammerlaan HS, Bonten MJ. Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis. J Antimicrob Chemother. 2012;67(6):1311\u201320.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"863_CR115","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/cc5019","volume":"10","author":"MJ Schwaber","year":"2006","unstructured":"Schwaber MJ, Carmeli Y. Antimicrobial resistance and patient outcomes: the hazards of adjustment. Crit Care. 2006;10(5):164.","journal-title":"Crit Care"},{"key":"863_CR116","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jclinepi.2018.01.012","volume":"111","author":"HJ Sch\u00fcnemann","year":"2019","unstructured":"Sch\u00fcnemann HJ, Cuello C, Akl EA, Mustafa RA, Meerpohl JJ, Thayer K, et al. GRADE guidelines: 18. How ROBINS-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence. J Clin Epidemiol. 2019;111:105\u201314.","journal-title":"J Clin Epidemiol"},{"issue":"9596","key":"863_CR117","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453\u20137.","journal-title":"Lancet"}],"container-title":["Antimicrobial Resistance &amp; Infection Control"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13756-020-00863-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13756-020-00863-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13756-020-00863-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T11:18:55Z","timestamp":1607599135000},"score":1,"resource":{"primary":{"URL":"https:\/\/aricjournal.biomedcentral.com\/articles\/10.1186\/s13756-020-00863-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":117,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["863"],"URL":"https:\/\/doi.org\/10.1186\/s13756-020-00863-x","relation":{},"ISSN":["2047-2994"],"issn-type":[{"value":"2047-2994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"28 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SAM: reports contracts from Health Canada, Public Health Agency of Canada and Ontario Ministry of Agriculture, Food and Rural Affairs, all outside the scope of the submitted work. All other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"200"}}